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Background: Accurate estimates of the size of the drug-using populations are essential for evidence-based policy
making. However, drug users form a ‘hidden’ population, necessitating the use of indirect methods to estimate
population sizes.
Methods: The benchmark-multiplier method was applied to estimate the population size of ever injecting drug
users (ever-IDUs), aged 18–64 years, in Belgium using data from the national HIV/AIDS register and from a
sero-behavioral study among injecting drug users. However, missing risk factor information and absence of follow-up
of the HIV+/AIDS– cases, limits the usefulness of the Belgian HIV/AIDS register as benchmark. To overcome these
limitations, statistical corrections were required. In particular, Imputation by Chained Equations was used to correct
for the missing risk factor information whereas stochastic mortality modelling was applied to account for the
mortality among the HIV+/AIDS– cases. Monte Carlo simulation was used to obtain confidence intervals, properly
reflecting the uncertainty due to random error as well as the uncertainty associated with the two statistical
corrections mentioned above.
Results: In 2010, the prevalence (/1000) of ever-IDUs was estimated to be 3.5 with 95% confidence interval [2.5;4.8].
No significant time trends were observed for the period 2000–2010.
Conclusions: To be able to estimate the ever-IDU population size using the Belgian HIV/AIDS register as benchmark,
statistical corrections were required without which seriously biased estimates would result. By developing the
improved methodology, Belgium is again able to provide ever-IDU population estimates, which are essential to
assess the coverage of treatment and to forecast health care needs and costs.
Keywords: Population size estimation, Ever injecting drug use, Benchmark-multiplier method, HIV/AIDS register,
Imputation by Chained Equations, Stochastic mortality modellingBackground
Accurate estimates of the size of the drug-using popula-
tion are indispensable to govern and evaluate drug pol-
icy. They are particularly important to forecast health
care needs and costs and to assess the coverage of
treatment and harm reduction measures e.g. [1,2].
However, drug users form a `hidden’ population, hiding
their membership because it involves illegal and stigma-
tized behaviour. As a result, `hidden’ populations lack* Correspondence: kaatje.bollaerts@wiv-isp.be
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reproduction in any medium, provided the orsampling frames and classical epidemiological methods
(e.g. population-based surveys) fail. Therefore, indirect
estimation methods are to be used. Generally, three
types of indirect estimation methods are distinguished
to estimate the size of drug using populations: capture-
recapture (CR), benchmark-multiplier (BM) and multi-
variate indicator (MI) methods [3-5]. An application of
the BM method is presented in this paper.
The BM method is a very intuitive method, relatively
easy to apply and hence, frequently used [6]. The BM
method combines (an estimate of) the size of the known
part of the target population, the benchmark, with an es-
timate of the proportion of individuals from the targetl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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of the proportion is called the multiplier. The size of the
target population is then estimated as the product of the
benchmark and the multiplier. Common sources used as
benchmark are mortality registers, HIV/AIDS registers,
drug treatment or police data e.g. [7,8]. During the be-
ginning of the 1970s, the mortality multiplier method
was already used [9]. Multiplier methods e.g. [10,11]
have produced estimates consistent with estimates pro-
duced by CR methods, which have been put forward as
a preferred methodology [6]. The key assumptions
underlying the BM method are that the benchmark
should be exhaustive, the sample used to estimate the
multiplier should be representative of the target popula-
tion and the case definition used for the benchmark
should exactly match the one used for the multiplier, in-
cluding the time window [12].
In this paper, the benchmark-multiplier (BM) method
was applied to estimate the prevalence of ever injecting
drug users (ever-IDUs) within the population aged
15–64 years in Belgium, 2000–10, using the HIV/AIDS
register as benchmark. In Belgium, HIV-screening is
widely used and all sera of which the screening test re-
sult was positive, are submitted for confirmation to one
of the seven AIDS Reference Laboratories (ARLs) in
Belgium. The registration results of all ARLs are then
send to the national HIV/AIDS register. As the seven
ARLs are the only laboratories subsidized for performing
HIV confirmation tests, the Belgian HIV/AIDS register is
deemed to be exhaustive and hence, constitutes a potential
suitable benchmark.
For Belgium, the latest estimate of the ever-IDU preva-
lence date from 1995 and was obtained adopting the BM
approach using the HIV/AIDS register as benchmark
[13]. However, the Belgium HIV/AIDS register suffers
from missing risk factor information. Particularly, of all
registered cases in 2000–10, 28.6% were reported without
information on probably mode of HIV transmission (e.g.
sexual contact, blood transfusion, injecting drug use).
Simply discarding these cases from analysis would lead
to an underestimation of the IDU prevalence. Simply ex-
trapolating the risk factor fractions of the subpopulation
for which the risk factors are known to the subpopula-
tion for which they are unknown, would lead to overcon-
fident results and would only lead to unbiased results
under very strict assumptions (i.e. the Missing Com-
pletely ad Random assumption). In addition, the national
HIV/AIDS register lacks follow-up of the non-AIDS
cases, implying absence of information on the vital status
of the HIV+/AIDS– cases. Not accounting for the mortality
among these cases would result in an overestimation of the
number of alive seropositive IDUs, with the bias increasing
as the time since the onset of the HIV-epidemic (mid-
eighties) increases. The methodology proposed in [13] useda simple extrapolation method to account for the missing
risk factor information and failed to account for the mor-
tality among HIV+/AIDS– cases. Therefore, the current
paper presents an improved application of HIV/AIDS BM
method, using up-to-date statistical methods to correct for
the missing risk factor information and lacking follow-up
of the HIV+/AIDS– cases.
Methods
Benchmark: national HIV/AIDS register
During 2000–10, an average of 56 screening tests per
1000 inhabitants per year were performed in Belgium,
excluding tests related to blood donations (National In-
stitute for Sickness and Invalidity Insurance). The con-
firmation tests are performed by one of the seven ARLs
in Belgium, being the only laboratories subsidized for
performing these tests. The registration results of the
seven ARLs are validated for duplicate recording and are
all included in the national HIV/AIDS register, being
hosted by the Scientific Institute of Public Health,
Brussels (WIV-ISP). Since its foundation in 1985–86, the
Belgian HIV/AIDS register is deemed to be exhaustive.
For each confirmed HIV-positive test, a standardized
form is sent to the patient’s clinician to collect additional
information on nationality, residence, sexual orientation,
probable mode of HIV transmission and CD4 count at time
of HIV diagnosis. The response categories for the self-
reported probable mode of HIV transmission are homo-
and heterosexual transmission, transmission through blood
transfusion, transmission through injecting drug use and
mother-to-child transmission. A person can indicate mul-
tiple modes of transmission. Unfortunately, the standard-
ized forms are not always fully completed returned to the
WIV-ISP, resulting in missing risk factor information.
Follow-up is conducted for patients who developed AIDS
with each year data being collected on last consultation
and possible death. The variables available for the AIDS
cases are year at AIDS-diagnosis, year at death and year at
lost to follow-up, which are only completed upon occur-
rence of the event and hence, are time dependent. The
HIV+/AIDS– cases are not subject to follow-up.
Multiplier: sero-behavioral prevalence study
In Belgium, a sero-behavioral study among drug users in
contact with drug treatment facilities or imprisoned was
carried out in 2004–05 [14]. In total, 1005 drug users in
treatment and 117 incarcerated drug users (15–40 years)
enrolled at 65 different drug treatment facilities and 15 dif-
ferent prisons geographically dispersed over Belgium, re-
spectively, participated to the study. Of the drug users in
treatment and in prison, 57% (n = 573) and 68% (n = 80)
declared to have injected drugs at least once during their
life. Intravenous blood samples were taken to determine
the HIV- as well as the Hepatitis B and -C status of the
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treatment and in prison was estimated to be 2.8% (95%
Wald CI: [1.5;4.2]) and 5% (95% Wald CI:[0.2;9.9]), respect-
ively. These prevalences were not significantly different
(p-value = 0.30), yielding an overall estimated prevalence
of 3.1% (95% Wald CI: [1.8;4.8]).
In addition to serological studies, the HIV prevalence
among IDUs in Belgium can be obtained from routine
diagnostic testing, of which the results are yearly available.
This allows the investigation of time trends. However, a
concern regarding the (geographical) representativeness of
the Belgian data exists. In line with (Western) European
trends [15], no significant time trends in HIV prevalences
among IDUs were observed during the last 10 years in
Belgium based on the results from routine diagnostic
testing [16]. Therefore, the HIV prevalence from the
sero-behavioral study was assumed to apply for the entire
period 2000–10.
Statistical methods
An estimate of the prevalence of ever-IDUs was obtained
by means of the BM method. For the current applica-
tion, the benchmark Nx was the number of alive sero-
positive ever-IDUs (aged 18–64 years) in Belgium for a
given year. The benchmark Nx was obtained from the
national HIV/AIDS register after correcting for the miss-
ing risk factor information using Imputation by Chained
Equations [17-19] and after correcting for the lacking in-
formation on the vital status of the HIV+/AIDS– cases
using stochastic mortality modelling [20]. The multiplier
π was then the reciprocal of the HIV-prevalence among
the ever-IDUs, for which an estimate could be obtained
from the sero-behavioral study by Plasschaert et al. [14].
A 3-step Monte Carlo simulation model was built to
generate (interval) estimates of the prevalence of ever-
IDUs. A schematic overview of the 3-step simulationTable 1 Schematic overview of the 3-step Monte Carlo simula
STEP 1: Imputation by Chained Equations: missing risk factor info
Missing risk factor information was imputed using Imputation
injecting drug use, sex, nationality, year at registration and ag
containing original and imputed values.
STEP 2: Stochastic Mortality Modeling: lacking follow-up of the H
For a complete dataset k, the number of registered HIV-cases
transmission and who were alive at time t is calculated as N^kxð
where Ii indicates the ‘vital’ status with Ii = 1 if person i is stil
of years since HIV registration or ri = t − thi and where pd is th
pd ~ betapert*(0.58%, 1.08%, 1.58%).
STEP 3: Benchmark-multiplier method: population size estimation
The number of ever-injecting drug users being alive at time t
obtained from step 2, p^HIVebeta 21; 620ð Þ and n = 639.
Ɨ The model was run K = 1000 times.
* The betapert distribution is mainly used to model expert estimates and requires amodel is provided in Table 1. The different steps within
the simulation model are described in more detail below.
This model was run K = 1000 times, yielding K = 1000
different estimates of the ever-IDU prevalence, based on
which the 95% percentile Monte Carlo confidence inter-
vals (95% MC CIs) were calculated.
Step 1: To correct for the missing risk factor information,
Imputation by Chained Equations (ICE) was used.
ICE is an iterative technique that starts by filling
in the missing values in a simple way, e.g. by
using mean imputation [17-19]. Then, each
variable included in the imputation model Xi,
i = 1, 2,…q, is imputed in turn by the
predictions of the regression model regressing
the observed values of Xi on the observed and
imputed values of the remaining variables
within the imputation model. The iteration
through all q variables constitutes one cycle.
After a sufficient number of cycles (typically
10 cycles), the final imputations are retained,
resulting in one ‘complete’ dataset. There are
several software packages available providing
(M)ICE procedures, i.e. STATA [21], S-PLUS
or R [22]. For the current application, ICE
as implemented in STATA was used to
account for the missing risk factor
information. In particular, the imputation
model included all (auxiliary) variables that
had a statistically significant association with
the variable indicating whether injecting
drug use was the most probable route of
transmission; being sex, nationality, year at
registration and age at registration. For every
run k (k = 1,2,…K = 1000), one ‘complete’
dataset was generated.tion model to estimate ever IDU prevalencesƗ
rmation
by Chained Equations. The imputation model contains the variables:
e at registration. The imputation results in one complete dataset Xk,
IV+/AIDS– cases







3 i ¼ 1
  tð Þ with Iki ¼
0; Td i < t or T l i < t
1; Ta i ≥ t or Td i ≥ t or T l i ≥ t
Siebern 1 pdð Þrið Þ; otherwise;
8<
:
l alive and living in Belgium and Ii = 0 otherwise, where ri is the number
e annual non-AIDS mortality rate among seropositive IDUs with
is given by N^ky tð Þ ¼ p^1HIV N^kx tð Þ−n1N^kx tð Þ 1−p^HIVð Þp^1HIV ; with N^kx tð Þ
















Bollaerts et al. Archives of Public Health 2013, 71:10 Page 4 of 6
http://www.archpublichealth.com/content/71/1/10Step 2: Binomial stochastic mortality modelling was
applied to correct for the lacking information on
the vital status of the HIV+/AIDS– cases. More
precisely, the vital status of a HIV+/AIDS– case i
was simulated using a binomial process having
survival probability pi ¼ 1 pdð Þri with ri being
the number of years since HIV registration,
implying lower survival probabilities when the
time since HIV-registration increases. The non-
AIDS crude mortality rate among IDUs (pd) was
assumed to follow a betapert distribution [23]
with minimum, most likely and maximum values
of 0.58%, 1.08% and 1.58% per annum,
respectively. These non-AIDS crude mortality
rates were calculated by Degenhardt et al. [24]
based on 44 cohort-studies. The vital status of the
AIDS cases at time t was deduced from the
AIDS-specific variables year at AIDS-diagnosis
(Ta), year at death (Td), and year at lost to follow-
up (Tl). In particular, an AIDS case was indicated
to be alive at time t if any information was
recorded after time t (i.e. if Ta ≥ t or Td ≥ t or
Tl ≥ t). On the other hand, an AIDS case was
indicated to be death at time t if the person died
before time t or was lost to follow-up. In the
latter case, the person is most likely to be death
or to have left the country.
Step 3: The Benchmark Multiplier method was
obtained to estimate the size Ny of the partly
‘hidden’ population or the target population as
N^ y ¼ N^ x
π^
; ð1Þ
having estimated benchmark N^ x and estimated
multiplier π^−1. However, even if N^ x and π^ are
unbiased estimators, N^ y is a biased estimator ofble 2 Results of the Monte Carlo (MC) simulation study estim
elgium, 2000-10
Number of seropositive IDUs Number of alive seroposit
ar Est*. 95% MI CI Ɨ Est*. 95% M
00 845 [814;877] 642 [612
01 876 [848;906] 659 [630
02 909 [879;940] 682 [654
03 961 [932;993] 723 [692
04 995 [964;1028] 744 [712
05 1009 [978;1042] 749 [719
06 1031 [997;1063] 758 [726
07 1061 [1029;1095] 779 [747
08 1080 [1049;1112] 792 [761
09 1094 [1062;1127] 798 [766
10 1113 [1079;1147] 809 [775
st.: mean estimate; Ɨ 95% MC CI: 95% Monte Carlo Confidence Intervals.Ny because of its non-linearity with respect to π^ .
Therefore, the bias-corrected estimator as
proposed in (Bollaerts K, Sasse A, Aerts M: The
benchmark-multiplier method: bias and new bias-











with n being the size of sample used to estimate
π . Observe that the sample size n is the only
additional piece of information needed to
construct the bias-corrected estimator as
compared to the traditional estimator. Then, the
estimate of the benchmark N^ x was obtained from
step 1 and 2 whereas the estimate π^ and the
corresponding sample size n were derived from
the sero-behavioral prevalence study [14]. As the
study indicated that x = 20 out of the n = 639
ever-IDUs were seropositive, π^ was assumed to
follow a beta distribution with π^ebeta
xþ 1; n−xþ 1ð Þ or π^ebeta 21; 620ð Þ [25].Results
After having corrected for missing risk factor information,
a total of 845 HIV-cases (aged 18-64yrs) with the HIV-
infection probably related to injecting drug use has been
identified in Belgium up to the year 2000. This number in-
creased to 1113 in 2010. Correcting for HIV+/AIDS– mor-
tality, these numbers dropped to 642 and 809 alive HIV+
ever-IDUs in 2000 and 2010, respectively. In 2010, the total
number of ever-IDUs (aged 18-64yrs) was estimated to be
24664 (95% MC CI: [17565;34403]) with the corresponding
prevalence (/1000) being 3.5 (95% MC CI: [2.5;4.8]). No
significant time trends in the number of ever-IDUs were
observed (Table 2).ating the prevalence of ever Injecting Drug Use (IDU),
ive IDUs Number of alive IDUs Prevalence (/1000)
I CI Ɨ Est*. 95% MI CI Ɨ Est*. 95% MI CI Ɨ
;673] 19497 [13540;27010] 2,9 [2.0;4.0]
;690] 19989 [14147;27663] 3 [2.1;4.1]
;713] 20721 [14724;28166] 3,1 [2.2;4.2]
;755] 22191 [15927;30659] 3,3 [2.3;4.5]
;775] 22861 [16220;31947] 3,4 [2.4;4.7]
;781] 22653 [15743;31955] 3,3 [2.3;4.7]
;790] 23178 [16362;31976] 3,4 [2.4;4.6]
;812] 23704 [16583;32937] 3,4 [2.4;4.7]
;826] 24026 [16844;32958] 3,4 [2.4;4.7]
;831] 24358 [17013;33951] 3,4 [2.4;4.8]
;842] 24664 [17565;34403] 3,5 [2.5;4.8]
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To obtain recent estimates of the ever-IDU prevalence
in Belgium, an improved HIV multiplier method was
applied. The improved methodology allows using the
Belgian HIV/AIDS register as benchmark while account-
ing for missing risk factor information (through Imput-
ation by Chained Equations - ICE) and lacking follow-up
of the HIV+/AIDS– cases (through stochastic mortality
modelling). The statistical corrections were implemented
in the best possible way. Indeed, ICE is a very flexible im-
putation approach, that can deal with several incomplete
variables, does not require specific missing data patterns
and operates under the less stringent assumption that
the probability of the missing values depends only on the
observed values and not on unobserved values (the so-
called Missing at Random assumption, [26]) [17-19]. The
stochastic mortality model accounts for the uncertainty
in the mortality rate and the Monte Carlo simulation
model properly acknowledges the uncertainty associated
with the statistical corrections mentioned above.
In 2010, the prevalence (per 1000 inhabitants, 15–64
years) of ever injecting drug use in Belgium was esti-
mated to be 3.5 (95% CI: 2.5-4.8), with no significant
time trends being observed for the period 2000–10.
Similar findings were reported by the other European
countries providing time trends of the national preva-
lence of ever injecting drug use, i.e. Norway, Cyprus and
the Czech republic [15]. This absence of a time trend is
seemingly in contrast with recent findings from the
EMCDDA treatment demand indicator, suggesting a de-
cline in recent-onset heroin users and heroin injectors in
the Western European countries [27]. However, it need
to be stressed that the prevalence of ever injecting drug
use is less sensitive to recent trends in drug use.
The above mentioned results should also be regarded
in the light of the assumptions underlying the BM
method. Particularly, the BM estimates rely on the condi-
tions that the benchmark is complete and that the multi-
plier is estimated based on a representative sample of the
target population. As benchmark of the current analysis,
the national HIV/AIDS register was used. Since its foun-
dation, the Belgian HIV/AIDS register is deemed to be
exhaustive as it includes the results of all Belgian labora-
tories subsidised for performing HIV confirmation tests.
As not only AIDS cases but also HIV cases are registered,
the Belgian HIV/AIDS register has the additional advan-
tage that back-calculation methods are not needed to ob-
tain the HIV prevalence. The multiplier was obtained
from a national sero-prevalence study including 653
IDUs [14]. Although this is the largest and most recent
Belgian sero-prevalence study, it did not include IDUs
outside treatment/prison, for whom currently no infor-
mation is available. Despite the fact that low threshold
drugs services are common in Belgium, the possibility ofbias resulting from a multiplier derived from a sample
that is not fully representative of the target population
cannot be ruled out.
To summarize, the current paper provides a thor-
ough application of the BM method. Nevertheless, the
use of such indirect methods inherently relies on em-
pirically non-verifiable (but reasonable) assumptions,
such as the representativeness of the multiplier. There-
fore, the current estimate of the ever IDU prevalence
should be complemented with estimates based on
other data sources (e.g. substitution treatment register)
and/or using other methods (e.g.capture-recapture, multi-
variate indicator method) (e.g. [28]). For now, it is (reason-
ably) assumed that the HIV prevalence among IDUs
remained stable during the last ten years. However, new
prevalence estimates are needed for future applications of
the BM method based on the Belgian HIV/AIDS register.
Finally, this paper presents estimates of the ever IDU
prevalence, which are important to assess future health
care needs regarding e.g. Hepatitis C treatment. However,
when interest is in assessing the coverage adequacy of
needle exchange programmes (NEPs) or opioid substitu-
tion treatment (OST), national estimates of the current
IDU prevalence are required. The latter prevalence (per
1000 inhabitants, 15–64 years) can be roughly estimated as
1.4 (95% CI: 1.02-1.97) by multiplying the ever-IDU preva-
lence with the ratio between current injectors and ever in-
jectors (r = 41%) among all treatment demands as
provided by the treatment demand indicator [29].
Conclusion
As the latest estimates of the prevalence of ever-IDUs for
Belgium date from 1995 [13], obtaining new estimates was
prioritized. To be able to estimate the ever-IDU population
size adopting the BM approach using the Belgian HIV/
AIDS register as benchmark, statistical corrections were
required. In particular, not accounting for the mortality
among HIV+/AIDS– cases would nowadays results in ser-
iously biased estimates. By developing the improved meth-
odology, recent ever-IDU population estimates for Belgium
could be obtained. These estimates are essential to monitor
trends over time and to forecast health care needs and
costs (e.g. for Hepatitis C treatment).
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